Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01083264 | Oct 2009 → May 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT02550977 | Sep 2015 → Jul 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01204190 | Sep 2010 → Jul 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00896571 | Jul 2009 → May 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00915915 | Jun 2009 → Apr 2010 | anovulation | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00933179 | Jun 2009 → Sep 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00873483 | Apr 2009 → Mar 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00729404 | Aug 2008 → Feb 2009 | anovulation | Bayer | Terminated | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT00920985 | Jun 2009 → Aug 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00910637 | May 2009 → Dec 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00984789 | May 2009 → Sep 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00914693 | Apr 2009 → Sep 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00185354 | Nov 2004 → Apr 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03077555 | Jan 2017 → Feb 2018 | anovulation | Mahidol University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03230825 | Sep 2017 → Sep 2018 | — | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT01372293 | Jan 2005 → Jan 2008 | polycystic ovary syndrome | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03881904 Comparator | Jun 2017 → Jul 2019 | female infertility | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00517556 Comparator | Aug 2007 → Mar 2011 | dysmenorrhea | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03531437 Comparator | Mar 2016 → Jan 2018 | thrombophilia | Mahidol University | Terminated | No outcome recorded |
| Phase 4 | NCT01056042 Comparator | Jun 2007 → Apr 2011 | endometriosis | Prince of Songkla University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06396221 Comparator | May → Sep 2024 | anovulation | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT06396208 Comparator | May → Oct 2024 | anovulation | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT03890042 Comparator | Mar 2019 → Jul 2020 | adenomyosis | Assiut University | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gestodene | “treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles” NCT00517556 ↗22“0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin)” NCT00185354 ↗ “quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene” NCT03077555 ↗ “7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen” NCT00896571 ↗ “Brand name :FLAME containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene.” NCT03230825 ↗ “ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles” NCT01372293 ↗ |
| Known as | Gestodeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL1213583 ↗ |
| Known as | GSD | “The aim of this study was to investigate the bleeding pattern and cycle control of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453585 ↗ Oct 20147“OBJECTIVE(S): To investigate the bleeding pattern and cycle control parameters of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453582 ↗ Oct 2014 “0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free...” NCT01204190 ↗ “7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen” NCT00896571 ↗ “7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen” NCT00914693 ↗ “Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene” NCT00915915 ↗ “Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)” NCT00185354 ↗ “Ethinylestradiol (EE) and Gestodene (GSD)” NCT01083264 ↗ |
| Known as | SH B 331 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1213583 ↗ |
| Action | Activate | “Progesterone receptor agonist” CHEMBL1213583 ↗ |
| Action | Inhibit | “Inhibition of Ovulation” NCT00915915 ↗ |
| Modality | Small molecule | — CHEMBL1213583 ↗ |
| Route | Other | “contraceptive patch SH P00331F” NCT00185354 ↗ |
| Target | PGR | “Progesterone receptor agonist” CHEMBL1213583 ↗ |